166 related articles for article (PubMed ID: 29521822)
1. Perioperative Management of Biologic and Immunosuppressive Medications in Patients With Crohn's Disease.
Lightner AL
Dis Colon Rectum; 2018 Apr; 61(4):428-431. PubMed ID: 29521822
[No Abstract] [Full Text] [Related]
2. [Medical management of pediatric Crohn's disease].
Zeng Y; Gong S
Zhonghua Er Ke Za Zhi; 2014 May; 52(5):345-8. PubMed ID: 24969931
[No Abstract] [Full Text] [Related]
3. Biological therapy for Crohn's disease in a liver transplant patient.
Bendezú García RA; Rodríguez Manrique MA; Hernández Martínez A; Lázaro Sáez M; Patrón Román GO; Amat Alcaraz S; Vega Sáenz JL
J Dig Dis; 2013 Oct; 14(10):564-6. PubMed ID: 23437819
[No Abstract] [Full Text] [Related]
4. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients.
Indar AA; Young-Fadok TM; Heppell J; Efron JE
World J Surg; 2009 May; 33(5):1049-52. PubMed ID: 19277774
[TBL] [Abstract][Full Text] [Related]
5. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
6. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?
White EC; Melmed GY; Vasiliauskas E; Dubinsky M; Ippoliti A; McGovern D; Targan S; Fleshner P
Dis Colon Rectum; 2012 May; 55(5):563-8. PubMed ID: 22513435
[TBL] [Abstract][Full Text] [Related]
7. Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn's disease.
Saito Y; Hayashi S; Gonmori T; Hamasaki Y; Igawa K
Int J Dermatol; 2020 May; 59(5):e159-e160. PubMed ID: 32034760
[No Abstract] [Full Text] [Related]
8. Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab.
Elmoursi A; Barrett TA; Perry C
Inflamm Bowel Dis; 2020 Jun; 26(7):e62-e63. PubMed ID: 32386054
[TBL] [Abstract][Full Text] [Related]
9. Risk mitigation in Crohn's disease and ulcerative colitis: Session four summary.
Leong RW
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():27-28. PubMed ID: 33817847
[No Abstract] [Full Text] [Related]
10. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease?
Tursi A
Aliment Pharmacol Ther; 2013 Apr; 37(7):752. PubMed ID: 23458532
[No Abstract] [Full Text] [Related]
11. [Adalimumab vasculitis in a patient with Crohn's disease].
Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
[No Abstract] [Full Text] [Related]
12. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531
[No Abstract] [Full Text] [Related]
13. Top-down in the Long Term in Crohn's Disease.
Boyapati RK; Ho GT; Satsangi J
J Crohns Colitis; 2018 Apr; 12(5):513-514. PubMed ID: 29548025
[No Abstract] [Full Text] [Related]
14. Emerging issues in the medical management of Crohn's disease.
Targownik LE; Coneys JG; Dhillon AS
Curr Opin Gastroenterol; 2016 Mar; 32(2):103-9. PubMed ID: 26839964
[TBL] [Abstract][Full Text] [Related]
15. Type and Quantity of Pharmacologic Therapy for Crohn's Disease before Eventual Surgical Treatment.
Kamiński JP; Miraflor E; Zaghiyan K; Fleshner P
Am Surg; 2016 Oct; 82(10):989-991. PubMed ID: 27779990
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of active tuberculosis following resumption of anti-TNF-α therapy in a patient with Crohn's disease.
Masiá M; Martínez M; García-Sepulcre MF; Sáez J; Gutiérrez F
Int J Tuberc Lung Dis; 2014 Feb; 18(2):249-50. PubMed ID: 24429322
[No Abstract] [Full Text] [Related]
17. [Prevention of post-surgical recurrence of Crohn's disease. A perspective].
Paviotti A; Terrosu G; Avellini C; Girometti R; Sorrentino D
Recenti Prog Med; 2009 May; 100(5):233-8. PubMed ID: 19772213
[TBL] [Abstract][Full Text] [Related]
18. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease.
El-Hussuna A; Andersen J; Bisgaard T; Jess P; Henriksen M; Oehlenschlager J; Thorlacius-Ussing O; Olaison G
Scand J Gastroenterol; 2012 Jun; 47(6):662-8. PubMed ID: 22486168
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
Fortea-Ormaechea JI; González-Lama Y; Casis B; Chaparro M; López Serrano P; Van Domselaar M; Bermejo F; Pajares R; Ponferrada A; Vera MI; Martínez Montiel P; Gisbert JP; Pérez-Calle JL; López San Román A; Abreu L; Menchén LA; Marín-Jiménez I
Gastroenterol Hepatol; 2011; 34(7):443-8. PubMed ID: 21724297
[TBL] [Abstract][Full Text] [Related]
20. Early combined immunosuppression in Crohn's disease.
Badina L; Taddio A; Ventura A
Lancet; 2008 Jun; 371(9629):1995; author reply 1996-7. PubMed ID: 18555906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
